Argos to begin Phase III of renal carcinoma drug in combination with sunitinib
This article was originally published in Scrip
Executive Summary
Argos Therapeutics has reported plans to begin an international Phase III study investigating its lead candidate for metastatic renal carcinoma (mRCC), AGS-003, in combination with sunitinib in patients newly diagnosed with the disease based on updated Phase II data for the product.